Vectivbio Holding Ag Quick Ratio (VECT) starting from the fourth quarter 2022 to fourth quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vectivbio Holding Ag  (NASDAQ: VECT)

Vectivbio Holding Ag's Quick Ratio

VECT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2022, Quick Ratio deteriorated to 8.95 above company average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Quick Ratio than Vectivbio Holding Ag in fourth quarter 2022. While Quick Ratio total ranking in the fourth quarter 2022 has deteriorated compared to the prior quarter from 448 to 532.

Explain Quick Ratio?
How much Cash & cash equivalents VECT´s has?
What are VECT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VECT Quick Ratio (Dec 31 2022)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2021)
Q4
Y / Y Current Liabilities Change 43.98 % 43.98 % 43.98 % 43.98 % -
Y / Y Cash & cash equivalent Change 115.58 % 115.58 % -1.71 % 115.58 % 155.67 %
Quick Ratio MRQ 8.95 8.95 5.75 8.95 5.98
VECT's Total Ranking # 532 # 448 # 469 # 470 # 697
Seq. Current Liabilities Change 0 % 0 % 0 % 43.98 % 0 %
Seq. Cash & cash equivalent Change 0 % 55.77 % -35.8 % 115.58 % 0 %



Quick Ratio fourth quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 59
Healthcare Sector # 257
Overall Market # 532


Quick Ratio Statistics
High Average Low
8.95 7.37 5.75
(Dec 31 2022)   0




Financial Statements
Vectivbio Holding Ag's Current Liabilities $ 25 Millions Visit VECT's Balance sheet
Vectivbio Holding Ag's Cash & cash equivalent $ 221 Millions Visit VECT's Balance sheet
Source of VECT's Sales Visit VECT's Sales by Geography


Cumulative Vectivbio Holding Ag's Quick Ratio

VECT's Quick Ratio for the trailling 12 Months

VECT Quick Ratio

 (Dec 31 2022)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth 43.98 % 77.31 % 143.98 % 343.98 % -
Y / Y Cash & cash equivalent TTM Growth 78.12 % 76.24 % 85.15 % 251.24 % 654.74 %
Quick Ratio TTM 8.15 7.52 6.79 7.49 6.59
Total Ranking TTM # 4178 # 4138 # 4222 # 4266 # 766
Seq. Current Liabilities TTM Growth 8.27 % 9.01 % 9.91 % 10.99 % 33.33 %
Seq. Cash & cash equivalent TTM Growth 17.26 % 20.86 % -0.43 % 26.22 % 16.03 %

Quick ratio ranking by company, industry and sector >> Back to VECT Financial Strength Comparisons >> Go to Compare VECT Quick Ratio to its Competitors

On the trailing twelve months basis VECT Cash & cash equivalent more than doubled by 115.58 % in Q4 2022 year on year, faster than Current Liabilities, this led to increase in in Vectivbio Holding Ag's Quick Ratio to 8.15, above VECT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 188 other companies have achieved higher Quick Ratio than Vectivbio Holding Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from 4138 to 4178.

Explain Quick Ratio?
How much Cash & cash equivalents VECT´s has?
What are VECT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 189
Healthcare Sector # 1134
Within the Market # 4178


trailing twelve months Quick Ratio Statistics
High Average Low
8.95 7.6 5.98
(Dec 31 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Vor Biopharma Inc   23.38 $ 230.245  Millions$ 9.847  Millions
Cullinan Therapeutics Inc   22.17 $ 467.292  Millions$ 21.077  Millions
Hillevax Inc   21.42 $ 279.401  Millions$ 13.046  Millions
Vivosim Labs Inc   20.73 $ 28.675  Millions$ 1.383  Millions
Lenz Therapeutics Inc   20.56 $ 268.229  Millions$ 13.043  Millions
Genenta Science S p a   19.32 $ 33.370  Millions$ 1.727  Millions
Replimune Group Inc   19.06 $ 395.655  Millions$ 20.756  Millions
Prime Medicine Inc   19.05 $ 286.087  Millions$ 15.020  Millions
Aura Biosciences Inc   18.06 $ 188.831  Millions$ 10.457  Millions
Ginkgo Bioworks Holdings Inc   16.93 $ 1,315.792  Millions$ 77.709  Millions
Acumen Pharmaceuticals Inc   15.91 $ 177.605  Millions$ 11.162  Millions
Icosavax Inc   15.83 $ 218.307  Millions$ 13.788  Millions
Anavex Life Sciences Corp   15.27 $ 149.158  Millions$ 9.770  Millions
Apogee Therapeutics Inc   15.22 $ 151.890  Millions$ 9.980  Millions
Compugen Ltd  15.16 $ 83.708  Millions$ 5.523  Millions
Invivyd Inc   14.86 $ 371.991  Millions$ 25.031  Millions
Quince Therapeutics Inc   14.86 $ 45.602  Millions$ 3.069  Millions
Cardiff Oncology Inc   14.76 $ 105.267  Millions$ 7.133  Millions
Protara Therapeutics Inc  14.70 $ 84.370  Millions$ 5.740  Millions
Tarsus Pharmaceuticals Inc   14.07 $ 217.026  Millions$ 15.429  Millions
Neumora Therapeutics Inc   13.85 $ 371.884  Millions$ 26.859  Millions
Candel Therapeutics Inc   13.60 $ 70.058  Millions$ 5.151  Millions
Krystal Biotech Inc   13.14 $ 379.171  Millions$ 28.847  Millions
Lexeo Therapeutics Inc   12.97 $ 77.335  Millions$ 5.964  Millions
Fusion Pharmaceuticals Inc   12.54 $ 170.874  Millions$ 13.624  Millions
Century Therapeutics inc   12.40 $ 369.735  Millions$ 29.817  Millions
Rubius Therapeutics Inc   12.07 $ 14.865  Millions$ 1.232  Millions
Achilles Therapeutics Plc  11.76 $ 173.338  Millions$ 14.738  Millions
Crispr Therapeutics Ag  11.67 $ 1,815.318  Millions$ 155.508  Millions
Springworks Therapeutics Inc   11.60 $ 592.212  Millions$ 51.049  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.